Opening Session Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Peter Clark, MA, MD, FRCP: A Payer Perspective

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

David A. Hyman, MD, JD, on Inclusive Shared Savings

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Apr

Today In Oncology

Opening Session Panel Discussion

Related Videos

Peter Clark, MA, MD, FRCP: A Payer Perspective

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

David A. Hyman, MD, JD, on Inclusive Shared Savings

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Focus on Optimized Dosing of Ibrutinib Panel Discussion

How Cannabis Use May Be Accelerating Breast and Testicular Cancer Rates in AYAs

Japanese Study Looks at Rates of Cancer Therapy–Related AML

Researchers Identify Blood-Based Biomarker for Cancer Risk in People With Lynch Syndrome

Final Report on Pralsetinib in Advanced RET Fusion–Positive NSCLC

New ASH HematOmics Program Offers Blood Cancer Data Integration Tool to Accelerate Research